NCT04176380View on ClinicalTrials.gov

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

June 6, 2023

Conditions
Relapsed, Refractory Multiple Myeloma
Interventions
BIOLOGICAL

RAPA-201 Autologous T cells

Autologous rapamycin resistant Th1/Tc1 cells

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

Rapa Therapeutics LLC

INDUSTRY

NCT04176380 - RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter